{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:55:05Z","timestamp":1793656505461,"version":"4.5.1"},"reference-count":38,"publisher":"American Society of Hematology","issue":"23","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,5]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Teclistamab is a B-cell maturation antigen (BCMA)\u2013directed bispecific antibody approved for the treatment of patients with triple-class exposed relapsed\/refractory multiple myeloma (R\/RMM). In the phase 1\/2 MajesTEC-1 study, a cohort of patients who had prior BCMA-targeted therapy (antibody-drug conjugate [ADC] or chimeric antigen receptor T-cell [CAR-T] therapy) was enrolled to explore teclistamab in patients previously exposed to anti-BCMA treatment. At a median follow-up of 28.0 months (range, 0.7-31.1), 40 patients with prior BCMA-targeted therapy had received subcutaneous 1.5 mg\/kg weekly teclistamab. The median prior lines of treatment was 6 (range, 3-14). Prior anti-BCMA therapy included ADC (n\u00a0=\u00a029), CAR-T (n\u00a0=\u00a015), or both (n\u00a0=\u00a04). The overall response rate was 52.5%; 47.5% of patients achieved very good partial response or better, and 30.0% achieved complete response or better. The median duration of response was 14.8 months, the median progression-free survival was 4.5 months, and the median overall survival was 15.5 months. The most common treatment-emergent adverse events (TEAEs) were neutropenia, infections, cytokine release syndrome, and anemia; cytopenias and infections were the most common grade \u22653 TEAEs. Infections occurred in 28 patients (70.0%; maximum grade 3\/4, n\u00a0= 13 [32.5%]; grade 5, n\u00a0=\u00a04 [10%]). Before starting teclistamab, baseline BCMA expression and immune characteristics were unaffected by prior anti-BCMA treatment. The MajesTEC-1 trial cohort C results demonstrate favorable efficacy and safety of teclistamab in patients with heavily pretreated R\/RMM and prior anti-BCMA treatment. This trial was registered at www.ClinicalTrials.gov as #NCT03145181 and #NCT04557098.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023023616","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T18:21:46Z","timestamp":1724350906000},"page":"2375-2388","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":75,"title":["Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies"],"prefix":"10.1182","volume":"144","author":[{"given":"Cyrille","family":"Touzeau","sequence":"first","affiliation":[{"name":"1Department of Hematology, University Hospital H\u00f4tel-Dieu, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8484-175X","authenticated-orcid":false,"given":"Amrita Y.","family":"Krishnan","sequence":"additional","affiliation":[{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Hospital H\u00f4tel-Dieu, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[{"name":"3Service d'H\u00e9matologie, Centre Hospitalier, Universitaire de Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7653-711X","authenticated-orcid":false,"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[{"name":"5Department of Hematology, University of Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"6IRCCS Azienda Ospedaliero-Universitaria di Bologna, Ser\u00e0gnoli Institute of Hematology, Department of Medical and Surgical Sciences, Bologna University School of Medicine, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Martinez Chamorro","sequence":"additional","affiliation":[{"name":"7Hematology Department, University Hospital Quir\u00f3nsalud and Universidad Europea, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[{"name":"8Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Martin","sequence":"additional","affiliation":[{"name":"9UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[{"name":"10Service d\u2019H\u00e9matologie Clinique, Centre Hospitalier Lyon Sud, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[{"name":"12Division of Hematology and Bone Marrow Transplantation, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Besemer","sequence":"additional","affiliation":[{"name":"13Department of Internal Medicine, University of Tubingen, Tubingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Pei","sequence":"additional","affiliation":[{"name":"14Janssen Research & Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Stein","sequence":"additional","affiliation":[{"name":"15Janssen Research & Development, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2013-372X","authenticated-orcid":false,"given":"Shun Xin","family":"Wang Lin","sequence":"additional","affiliation":[{"name":"15Janssen Research & Development, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Trancucci","sequence":"additional","affiliation":[{"name":"14Janssen Research & Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0044-4341","authenticated-orcid":false,"given":"Raluca I.","family":"Verona","sequence":"additional","affiliation":[{"name":"15Janssen Research & Development, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Girgis","sequence":"additional","affiliation":[{"name":"15Janssen Research & Development, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Miao","sequence":"additional","affiliation":[{"name":"15Janssen Research & Development, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa M.","family":"Uhlar","sequence":"additional","affiliation":[{"name":"15Janssen Research & Development, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Chastain","sequence":"additional","affiliation":[{"name":"14Janssen Research & Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2791-5748","authenticated-orcid":false,"given":"Alfred L.","family":"Garfall","sequence":"additional","affiliation":[{"name":"16Division of Hematology Oncology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2024120516204795100_bib1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2024120516204795100_bib2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2024120516204795100_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"issue":"14","key":"2024120516204795100_bib4","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024120516204795100_bib5","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"2024120516204795100_bib6","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"2024120516204795100_bib7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"2024120516204795100_bib8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/ijms24010645","article-title":"Innovative anti-CD38 and anti-BCMA targeted therapies in multiple myeloma: mechanisms of action and resistance","volume":"24","author":"De Novellis","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"10297","key":"2024120516204795100_bib9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2024120516204795100_bib10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024120516204795100_bib11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024120516204795100_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J"},{"key":"2024120516204795100_bib13","unstructured":"GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorization. 2022. Accessed 17 November 2023. https:\/\/us.gsk.com\/en-us\/media\/press-releases\/gsk-provides-an-update-on-blenrep-belantamab-mafodotin-blmf-us-marketing-authorization\/."},{"key":"2024120516204795100_bib14","unstructured":"EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep. 2023. Accessed 17 November 2023. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-non-renewal-authorisation-multiple-myeloma-medicine-blenrep."},{"key":"2024120516204795100_bib15","volume-title":"TECVAYLI. Summary of product characteristics","year":"2022"},{"key":"2024120516204795100_bib16","volume-title":"TECVAYLI (R) (teclistamab-cqyv) injection. Prescribing information","year":"2022"},{"key":"2024120516204795100_bib17","unstructured":"ELREXFIO-elranatamab-bcmm injection, solution. Highlights of prescribing information. Pfizer Inc. Accessed 17 November 2023. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19669."},{"key":"2024120516204795100_bib18","article-title":"Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","author":"van de Donk","year":"2-6  2023","journal-title":"Poster 8011 presented at the American Society of Clinical Oncology Annual Meeting"},{"issue":"16","key":"2024120516204795100_bib19","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1182\/bloodadvances.2019000466","article-title":"Serial treatment of relapsed\/refractory multiple myeloma with different BCMA-targeting therapies","volume":"3","author":"Cohen","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"2024120516204795100_bib20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive MM after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"2024120516204795100_bib21","unstructured":"Mathieu\n              E\n            , RitchieH, Rod\u00e9s-GuiraoL, . Coronavirus pandemic (COVID-19). 2020. Accessed 29 April 2024. https:\/\/ourworldindataorg\/coronavirus."},{"issue":"4","key":"2024120516204795100_bib22","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","article-title":"Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Girgis","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2024120516204795100_bib23","doi-asserted-by":"crossref","first-page":"e2238961","DOI":"10.1001\/jamanetworkopen.2022.38961","article-title":"Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma","volume":"5","author":"Hammons","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"8","key":"2024120516204795100_bib24","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","article-title":"Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2024120516204795100_bib25","doi-asserted-by":"crossref","first-page":"308.e1","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"2024120516204795100_bib26","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2023-190793","article-title":"Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM)","volume":"142","author":"Asoori","year":"2023","journal-title":"Blood"},{"key":"2024120516204795100_bib27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.HS9.0000829600.37424.88","article-title":"Results from the cc-220-mm-001 dose-expansion phase of iberdomide plus dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"6","author":"van de Donk","year":"2022","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2024120516204795100_bib28","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1182\/blood-2021-150998","article-title":"Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment","volume":"138","author":"Baljevic","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024120516204795100_bib29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"2024120516204795100_bib30","article-title":"Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): analysis of patient- and disease-related factors associated with responses","author":"Harrison","year":"27-30  2023","journal-title":"Athens, Greece: Paper presented at: International Myeloma Society 20th Annual Meeting and Exposition"},{"key":"2024120516204795100_bib31","author":"Jakubowiak","year":"9-12  2023"},{"issue":"1","key":"2024120516204795100_bib32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"key":"2024120516204795100_bib38","article-title":"Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma","author":"Tan","year":"9\u201312  2023","journal-title":"Poster 3347 presented at the 65th American Society of Hematology Annual Meeting"},{"key":"2024120516204795100_bib33","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","article-title":"Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","author":"van de Donk","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024120516204795100_bib34","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024120516204795100_bib35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"2","key":"2024120516204795100_bib36","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"6","key":"2024120516204795100_bib37","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/23\/2375\/2319058\/blood_bld-2023-023616-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/23\/2375\/2319058\/blood_bld-2023-023616-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T16:21:06Z","timestamp":1733415666000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/23\/2375\/517467\/Efficacy-and-safety-of-teclistamab-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":38,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023023616","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]}}}